The COVID-19 pandemic has stretched healthcare systems, forcing them to care for more patients with fewer staff. One immediate action...
For over ten years, Eviti Connect has empowered oncology practices and health plans to prescribe and reimburse high-quality, high-value patient care....
For over ten years, Eviti Connect has been empowering oncology practices and health plans to prescribe and reimburse high-quality, high-value...
Proven in oncology, the Eviti Connect payer solution expands to help reduce reimbursement inefficiencies and manage drug costs for disease...
We are excited about the recent launch of Eviti Connect® for autoimmune diseases, aimed at helping payers and providers realize...
Providers don’t want to delay patient care. Payers don’t want to waste money on unwarranted, ineffective autoimmune care. Both want...
Cancer care is costly and complex; and if you don’t have the tools needed to effectively manage your cancer spend,...
Strategic use of biosimilars in cancer care provides an opportunity for more value as these drugs frequently cost less than...
As oncology costs continue to escalate and treatment decisions are more complex than ever, Eviti Connect empowers providers and payers...
The cost of oncology-focused drugs in the U.S. has now exceeded $56 billion and the median annual expense of a new cancer...
NantHealth’s study data shows: Adoption of trastuzumab biosimilars in treatment of HER2-positive breast cancer is significant; does not appear to...
There is no doubt that COVID-19 has had a tremendous impact on the U.S. healthcare system, forcing everyone—from payers to...